CHU Amiens
Amiens, 80480, France
NCT Number: NCT03927079
Respiratory infections are common and sometimes very severe. An insufficient dosage of the antibiotic could lead to a treatment failure A correct plasmatic antibiotic concentration is not a guarantee of a clinical success as it could not be a reflect of pulmonary concentration. The aim of this study is to determinate the predictive factors of pulmonary penetration of antibiotics in patients with a beta lactamines failure and who undergoes a flexible bronchoscopy.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
Amiens, 80480, France
To check if pulmonary concentrations of antibiotic are enough we will measure antibiotic concentration in the broncho-alveolar lavage (BAL). This technique which is clinically relevant and reliable could determinate the pulmonary diffusion level for antibiotics by calculating the ratio between plasmatic and intra-alveolar antibiotic concentration. This ratio will be correlated with potential limitation factors of pulmonary diffusion as respiratory diseases (COPD, cystic fibrosis, fibrosis…), sepsis, hypoalbuminemia. We have chosen to study the beta lactamin antibiotics because they are the most frequently used in pneumonia. Moreover, the beta lactamins pulmonary diffusion is likely to be the lowest. Finally, for patients with a known pathogen, we will divide this pulmonary concentration with minimal inhibitory concentration (MIC). Indeed, in severe pneumonia, to be sure of bactericidal activity, a pulmonary concentration of beta lactamines should be always higher than 4 to 5 times MIC.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic
Time frame: on the day of the bronco-alveolar lavage
pulmonary diffusion level for beta lactamins is determined by ratio between bronchoalveolar concentration and plasmatic concentration of tested antibiotics
Time frame: from day of inclusion to 15 days after inclusion
measure of apyrexia duration in days
Time frame: from day of inclusion to 15 days after inclusion
duration in days for regression of the biological inflammatory syndrome (CRP concentration in mg/l divided by 2)
Time frame: from day of inclusion to 15 days after inclusion
measure of length of hospitalisation in days
Time frame: 28 days after inclusion
28-day mortality will be measured
Time frame: day of bronchoalveolar lavage (BAL)
virus presence will be detected in bronchoalveolar lavage (BAL)
Centre Hospitalier Universitaire, Amiens
Other
Acronym: ABBA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07016217
Antibiotics, Clindamycin
Vancouver, British Columbia, Canada
View Trial DetailsNCT06708689
Antibiotics, Botriomycoma
Bron, France
View Trial DetailsNCT04669717
Antibiotics, Mouth Diseases
Geneva, Canton of Geneva, Switzerland
View Trial DetailsNCT07246967
Antibiotics, Female Urogenital Diseases
Shanghai, Shanghai Municipality, China
View Trial Details